Financing, Equity Capital Markets

Revance Therapeutics, Inc.

12/19
|
$110.5 Million
Piper Sandler served as bookrunner for Revance Therapeutics, Inc on a confidentially marketed follow-on offering
Sub-Type
CMFO
Sub-Sector
Biopharma